Alector Inc Earnings
The next earnings date for Alector Inc is November 5, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of Alector Inc Earnings
| 11/05/2026 | $-0.25 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Alector Inc Earnings: Historical
| 08/06/2026 | After Market | $-0.21 | 12.50% |
| 05/07/2026 | After Market | $-0.21 | 22.22% |
| 03/03/2026 | --- | $-0.34 | 13.11% |
| 11/06/2025 | After Market | $-0.34 | 17.07% |
| 08/07/2025 | After Market | $-0.30 | 33.33% |
| 05/08/2025 | After Market | $-0.41 | 10.87% |
| 02/25/2025 | Before Market | $-0.02 | 96.33% |
| 11/06/2024 | After Market | $-0.43 | 18.87% |
| 08/07/2024 | After Market | $-0.40 | 16.67% |
| 05/08/2024 | After Market | $-0.38 | 22.45% |
More About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
“Alector Inc Earnings” Can Refer to the Alector Inc Earnings Date
Some people say “Alector Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Alector Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Alector Inc Stock on the Earnings Date
If you own Alector Inc stock (ALEC) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Alector Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Alector Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Alector Inc Earnings
You can contact us any time if you would like to ask questions about Alector Inc earnings or anything else related to the stock market.